To greatly help tackle many of the most vexing questions about Alzheimers disease.

AFAR announces new Collaborative Analysis Awards Plan in Alzheimer’s Disease The American Federation for Aging Study announced today a new grant program which will support collaboration among young scientists from different scientific disciplines, to greatly help tackle many of the most vexing questions about Alzheimer’s disease. Referred to as The Collaborative Analysis Awards Plan in Alzheimer’s Disease, the new initiative is supported by The Arthur and Rosalinde Gilbert Foundation and the Diane and Guilford Glazer Foundation, in partnership with AFAR, which manages the program. These investigators already are playing an integral role in the development of new knowledge about Alzheimer’s disease, said Stephanie Lederman, EdM, Executive Director, AFAR .

And also other changes, this prospects to neuronal loss of life and atrophy of the frontal lobes of the brain, leading to dementia ultimately. Genetic testing is available to discover the mutation, nonetheless it is costly. In ’09 2009, Mayo Clinic researcher Rosa Rademakers, Ph.D., and colleagues found that FTD patients with PGRN mutations demonstrated a decrease in blood progranulin amounts compared to handles and FTD individuals without PGRN mutations. Predicated on these findings and using A&G’s proprietary antibody reagents, Mayo experts developed an easy-to-use, cost-effective blood test for measuring the known level of progranulin. ‘The progranulin blood check has an inexpensive tool to recognize progranulin mutation carriers in individuals with early-onset dementia or asymptomatic relatives of FTD sufferers,’ says Alicia Algeciras-Schimnich, Ph.D.